Two patients, a 48-year-old woman and a 61-year-old man, with portal vein tumor emboli underwent pancreaticoduodenectomy combined with portal vein resection. In order to protect the liver during occlusion of the portal vein, we induced mild hypothermia with surface cooling and hepatic oxygen status was monitored by hepatic venous oxygen saturation (ShvO2). During the temporary occlusion of the portal vein, the woman showed a marked decrease in ShvO2, significantly lower than 20%, and continued for about one hour, but on the other hand the man did not. But as the body temperature was raised, they showed the same tendency of decreased ShvO2. Postoperatively, her serum GOT, GPT, T-bilirubin were 104 UI.dl-1, 58 UI.dl-1, 1.95 mg.dl-1 and his data were 62, 42, 1.01 respectively. No other complication were observed. These results suggest that ShvO2 monitoring and mild hypothermia are clinically useful in detecting hepatic oxygen supply/demand unbalance and in protecting the liver.
Download full-text PDF |
Source |
---|
CRSLS
January 2025
Department of Surgery, King Saud University Medical City, Riyadh, Saudi Arabia. (Drs. Aljunaydil, Mattar, Almufawaz, AlOthman, and Alalem).
Introduction: Acute appendicitis and acute cholecystitis are two of the most commonly encountered surgical entities. Multiple hypotheses are behind their coexistence, which include pathogen predilection, and mucosal ischemia inducing portal vein bacteremia as the management of uncomplicated acute cholecystitis and acute appendicitis is surgical, for which a single operation for synchronous presentation is effective. Here, we report a case with coexistent acute cholecystitis and acute appendicitis managed at our institution.
View Article and Find Full Text PDFGastroenterol Hepatol
January 2025
Servicio de Hepatología, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, España. Electronic address:
Portal hypertension is a hemodynamic abnormality that complicates the course of cirrhosis, as well as other diseases that affect the portal venous circulation. The development of portal hypertension compromises prognosis, especially when it rises above a certain threshold known as clinically significant portal hypertension (CSPH). In the consensus conference on Portal Hypertension promoted by the Spanish Association for the Study of the Liver and the Hepatic and Digestive diseases area of the Biomedical Research Networking Center (CIBERehd), different aspects of the diagnosis and treatment of portal hypertension caused by cirrhosis or other diseases were discussed.
View Article and Find Full Text PDFArab J Gastroenterol
January 2025
Department of Radiology, West China Hospital, Sichuan University, Chengdu, PR China. Electronic address:
Congenital extrahepatic portosystemic shunt, also known as Abernethy malformation, is a rare anatomic vascular malformation. Patients with Abernethy malformation may present with abdominal pain, abnormal liver function tests, hepatopulmonary syndrome, pulmonary hypertension, and/or portosystemic encephalopathy. Accurate identification of the shunt and portal vein and effective management of complications is vital in these patients.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
HuaShan Hospital, Fudan University, Shanghai, China, Shanghai, China.
Background: To investigate the physiological clearance of circulating Aβ by the liver and its role in the pathogenesis of Alzheimer's disease (AD).
Method: Immunostaining, near-infrared imaging, and flow cytometry were used to explore the physiological clearance of Aβ by the liver and the impact of aging on Aβ clearance. Liver-specific LRP-1 knockdown and functional LRP-1 minigene (mLRP-1) expression in mice with AD were used to explore the effects of hepatic Aβ clearance on AD pathogenesis and treatment.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, USA.
Background And Aims: We assessed clinical, procoagulant and genetic risk factors and clinical outcomes in dabigatran-treated patients with non-tumoural acute and acute-on-chronic portal vein thrombosis (PVT).
Methods: Patients with a new diagnosis of non-tumoural acute and acute-on-chronic PVT between January 2021 and January 2024 (aged ≥ 18 years) in those without/with cirrhosis (Child-Pugh (CP)-A/B/C ≤ 10) were started on dabigatran and followed and compared with those on vitamin K antagonist (VKA) and untreated individuals.
Results: Dabigatran was prescribed in 119 patients with PVT type 1 (61, 51.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!